Kane Biotech Inc.

Kane Biotech Inc.

August 03, 2006 11:18 ET

Kane Biotech Announces Publication of Scientific Discoveries

WINNIPEG, MANITOBA--(CCNMatthews - Aug. 3, 2006) - Kane Biotech Inc. (TSX VENTURE:KNE), a leading biofilm company, is pleased to announce the publication of recent scientific discoveries in the reputed scientific journals Antimicrobial Agents and Chemotherapy (AAC) and the Journal of Industrial Microbiology & Biotechnology (JIMB). These discoveries were made by Director of Research, Dr. Srinivasa Madhyastha, and the Kane Biotech research team.

The results of the in vitro study published in the May 2006 issue of AAC (Antimicrobial Agents and Chemotherapy, Vol. 50, p. 1835-1840), entitled "Antibiofilm Activity of GlmU Enzyme Inhibitors against Catheter-Associated Uropathogens", demonstrated that Kane Biotech's study compound, when coated on urinary catheters, was able to provide superior inhibition of the colonization of catheters by urinary tract infection associated bacteria when compared to currently marketed antimicrobial coated catheters.

The Kane Biotech compound in this study was one of several candidate products that came out of the Company's research program to develop and screen novel products with antibiofilm activity. This research program also yielded the discovery of KBI-5898, the Company's lead product for the antimicrobial coating of urinary catheters. In November 2005, Kane Biotech announced the results of an in vivo study in which KBI-5898 coated urinary catheters were shown to be significantly less likely to be colonized by bacteria than either currently marketed silver-hydrogel coated catheters or uncoated catheters. The study further showed that KBI-5898 coated urinary catheters were also significantly less likely to cause catheter related infections than either the silver-hydrogel coated or uncoated catheters.

Kane Biotech also announces the publication of a new biofilm assay method in JIMB (J Ind Microbiol Biotechnol, 2006), entitled "A Microplate Spectrofluorometric Assay for Bacterial Biofilms". In this manuscript Dr. Madhyastha and his team describe an assay for the quantification of bacterial biofilms in vitro. The assay developed by Kane Biotech is compared to the widely-used assay for quantifying bacterial biofilms. For the purposes of this study, biofilm formation was challenged with both Nitrofurazone, the active ingredient found in a currently marketed antimicrobial coated catheter, and dispersin B, one of Kane Biotech's novel antibiofilm compounds. In this study, Kane Biotech's assay is shown to be superior in terms of sensitivity and specificity when compared to the current standard assay.

"The publication of our work in peer-reviewed and reputed scientific journals, and the subsequent recognition of these discoveries by researchers in Canada and abroad clearly cements Kane Biotech's position as a leading biofilm researcher", stated Mr. Gord Froehlich, President of Kane Biotech. "It is a testament to both the technology and scientific capabilities of our company."

About Kane Biotech Inc.

Kane Biotech is a biotechnology company engaged in the development of products to prevent and disperse bacterial biofilms. Biofilms develop when bacteria, and other microorganisms, form a protective matrix that acts as a shield against attack. When in a biofilm, bacteria become highly resistant to antibiotics, high temperatures and host immune responses. This resiliency contributes to human health problems such as recurrent urinary tract infections, medical device associated infections and tooth decay.

Kane Biotech continues to aggressively pursue its commercialization strategy for KBI-5898. Infections caused by urinary catheters cost the United States healthcare system over US$1 billion per year. In addition, the Company is developing an oral care product based on its novel CSP technology for the prevention of dental plaque. The U.S. dental market is over US$70 billion per year, with over $3.7 billion spent on oral care alone.

Certain information contained in this press release may be forward-looking and is subject to risks and uncertainties. Although the Company believes that the expectations contained herein are reasonable, it can give no assurances such forward-looking statements will prove correct. Information is provided from sources deemed to be reliable.

The TSX Venture Exchange has neither approved nor disapproved the contents of this press release.

Contact Information